Delving into the Latest Updates on Beijing Jinchengtaier Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Mouth and Tooth Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

ER(Estrogen receptors)	1

主要目的：比较空腹和餐后给药条件下单次口服北京金城泰尔制药有限公司提供的富马酸比索洛尔片（规格：5 mg）与Merck Serono GmbH持证的富马酸比索洛尔片（商品名：康忻®（Concor®）；规格：5 mg）在健康人群中吸收程度和速度的差异，评价空腹和餐后状态下口服两种制剂的生物等效性。次要目的：评价空腹和餐后给药条件下单次口服北京金城泰尔制药有限公司提供的富马酸比索洛尔片（规格：5 mg）与Merck Serono GmbH持证的富马酸比索洛尔片（商品名：康忻®（Concor®）；规格：5 mg）的安全性和耐受性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of a single oral dose of bisoprolol fumarate tablets (specification: 5 mg) provided by Beijing Jincheng Taier Pharmaceutical Co., Ltd. and bisoprolol fumarate tablets (trade name: Concor®; specification: 5 mg) certified by Merck Serono GmbH in healthy people under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting and fed conditions. Secondary objective: To evaluate the safety and tolerability of a single oral dose of bisoprolol fumarate tablets (specification: 5 mg) provided by Beijing Jincheng Taier Pharmaceutical Co., Ltd. and bisoprolol fumarate tablets (trade name: Concor®; specification: 5 mg) certified by Merck Serono GmbH under fasting and fed conditions.

Start Date23 May 2023

Sponsor / Collaborator

Beijing Jinchengtaier Pharmaceutical Co., Ltd.

CTR20230457

/ CompletedNot Applicable

丁二磺酸腺苷蛋氨酸肠溶片在健康人群中的单中心、随机、开放、两制剂、四周期、完全重复人体生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, four-cycle, fully repeated human bioequivalence study of enteric-coated adenosylmethionine butanedisulfonate tablets in healthy subjects

主要研究目的：考察健康受试者在空腹及餐后条件下，单次口服1片由北京金城泰尔制药有限公司生产的丁二磺酸腺苷蛋氨酸肠溶片（受试制剂T，规格：0.5g）与相同状态下单次口服1片由ABBOTT LABORATORIES (M) SDN. BHD持证的丁二磺酸腺苷蛋氨酸肠溶片（参比制剂R，商品名：思美泰®，规格：0.5g）的药动学特征，评价两制剂的生物等效性，为该受试制剂注册申请提供依据。次要研究目的：观察健康受试者在空腹及餐后条件下单次口服受试制剂丁二磺酸腺苷蛋氨酸肠溶片（规格：0.5g）或参比制剂丁二磺酸腺苷蛋氨酸肠溶片（商品名：思美泰®，规格：0.5g）在中国健康受试者中的安全性。

[Translation]

Main study objectives: To investigate the pharmacokinetic characteristics of a single oral tablet of 1 tablet of 5-adenosylmethionine disulfonate enteric-coated tablets (test preparation T, specification: 0.5g) produced by Beijing Jincheng Taier Pharmaceutical Co., Ltd. and a single oral tablet of 1 tablet of 5-adenosylmethionine disulfonate enteric-coated tablets (reference preparation R, trade name: Sumeta®, specification: 0.5g) certified by ABBOTT LABORATORIES (M) SDN. BHD under the same conditions, evaluate the bioequivalence of the two preparations, and provide a basis for the registration application of the test preparation. Secondary study objectives: To observe the safety of a single oral administration of the test preparation 5-adenosylmethionine disulfonate enteric-coated tablets (specification: 0.5g) or the reference preparation 5-adenosylmethionine disulfonate enteric-coated tablets (trade name: Sumeta®, specification: 0.5g) in healthy subjects in China under fasting and postprandial conditions.

Start Date11 Mar 2023

Sponsor / Collaborator

Beijing Jinchengtaier Pharmaceutical Co., Ltd.

CTR20200104

/ CompletedPhase 4

匹多莫德分散片辅助治疗反复发作的尿路感染的有效性和安全性随机、双盲、安慰剂平行对照、多中心临床试验

[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial on the efficacy and safety of pidotimod dispersible tablets as an adjunctive treatment for recurrent urinary tract infections

主要研究目的：评价匹多莫德分散片辅助治疗反复发作的尿路感染的有效性次要研究目的：评价匹多莫德分散片辅助治疗反复发作的尿路感染的安全性

[Translation]

Primary study objective: To evaluate the effectiveness of pidotimod dispersible tablets as an adjunctive treatment for recurrent urinary tract infections Secondary study objective: To evaluate the safety of pidotimod dispersible tablets as an adjunctive treatment for recurrent urinary tract infections

Start Date07 Apr 2020

Sponsor / Collaborator

Inner Mongolia Kenuo Pharmaceutical Development Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Jinchengtaier Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Jinchengtaier Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Beijing Jinchengtaier Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Jinchengtaier Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data